Antitumor activity of satraplatin in cisplatin-resistant oral squamous cell carcinoma cells

  • Head Neck. 2011 Mar;33(3):309-17. doi: 10.1002/hed.21445.
Yukio Yamano  1 ,  Masashi Shiiba ,  Kenji Negoro ,  Ken Nakatani ,  Atsushi Kasamatsu ,  Masanobu Yamatoji ,  Kentaro Sakuma ,  Kenji Ogoshi ,  Manabu Iyoda ,  Keiji Shinozuka ,  Hidetaka Yokoe ,  Takeshi Wada ,  Shigeyuki Fujita ,  Shunichiro Iwasawa ,  Yuichi Takiguchi ,  Hideki Tanzawa ,  Katsuhiro Uzawa
Affiliations
  • 1. Department of Clinical Molecular Biology, Graduate School of Medicine, Chiba University, Chiba, Japan.
PMID: 20848452 DOI: 10.1002/hed.21445
Abstract

Background: The aim of the current study was to identify the antitumor activity of satraplatin in paired cisplatin (CDDP)-resistant oral Squamous Cell Carcinoma (OSCC) cell line and its parental cell line.

Methods: CDDP-resistant (KB-R) cells and parental cells (KB) pair were used. Viability was assessed using the MTT and clonogenic assay. Real-time polymerase chain reaction (PCR), glutathione (GSH) assay, and flow cytometric analysis were used for further assessment.

Results: KB-R cells did not show cross-resistance to satraplatin. The expression status of almost all transporters was upregulated in the KB-R cells. There was no difference in the GSH levels between the KB and KB-R cells. Flow cytometric analysis indicated that with satraplatin the G2/M phase was arrested in the KB-R cells. KB-R cells contain enriched side population cells.

Conclusion: These data suggested that satraplatin has antitumor activity against the CDDP-resistant OSCC cells. The mechanism of cross-resistance to platinum agents seems to be multifactorial.

Products